ScanSource (SCSC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Oct, 2026Executive summary
FY2026 net sales rose 6.1% to $3.23B; gross profit rose 7.0% to $437.4M, adjusted EBITDA rose 4.8% to $151.5M, and non-GAAP diluted EPS increased 18.8% to $4.24.
Gross margin expanded 20 bps to 13.6%; recurring revenue reached 33.7% of gross profit, up from 32.8%, and free cash flow was $113.8M.
MicroAge acquisition closed in September 2026, adding higher-margin capabilities in cloud, cybersecurity, data center and AI; expected to be accretive to gross margin, adjusted EBITDA margin and non-GAAP EPS in the first year after closing.
Fiscal 2027 priorities include profitable growth, recurring revenue, disciplined acquisitions, continued share repurchases and maintaining a strong balance sheet.
Voting matters and shareholder proposals
December 8, 2026 meeting agenda: elect seven directors, hold an advisory say-on-pay vote and ratify Deloitte & Touche LLP for FY2027; the Board recommends FOR each proposal.
October 2, 2026 is the voting record date; 20,367,768 common shares were outstanding, with one vote per share and no cumulative director voting.
Director election, say-on-pay and auditor ratification each require a majority of votes cast; broker discretion applies to auditor ratification, not the first two proposals.
Proposals for inclusion in the 2027 proxy must arrive by June 28, 2027; other nominations and proposals generally require notice August 10–September 9, 2027, subject to meeting-date changes.
Board of directors and corporate governance
Seven nominees stand for annual election through the 2027 meeting; six directors are independent, and Michael Baur serves as Chair and CEO with Charles Mathis as Lead Independent Director.
Peter Browning retired in August 2026 after more than 12 years on the Board; the Board reduced to seven members.
The Board met 11 times and its committees met 15 times in FY2026; all incumbent directors attended at least 75% of applicable meetings.
Board succession and performance reviews occur annually; annual elections apply, with no term limits or mandatory retirement age.
Shareholder outreach covered nearly 70% of outstanding shares; engagement calls involved holders representing approximately 60%, while seven investors representing nearly 50% accepted FY2027 outreach invitations.
Latest events from ScanSource
- Sales rose 30.1%, but margins and earnings fell; FY27 outlook increased.SCSC
Q1 2027 - Board backs all seven nominees, executive compensation, and Deloitte auditor ratification.SCSC
Proxy filing - Recurring revenue and strategic M&A drive margin expansion and sustainable growth.SCSC
Investor presentation - Strong Q4 and FY results, with MicroAge acquisition set to drive further margin and sales growth.SCSC
Q4 2026 - Recurring revenue and margin expansion drive growth, supported by disciplined capital allocation.SCSC
Investor presentation - Quarterly sales up 8.8% to $766.8M, strong cash flow, margin gains, and new business initiatives.SCSC
Q3 2026 - Recurring revenues and disciplined capital allocation drive margin growth and efficiency.SCSC
47th Annual Raymond James Institutional Investor Conference - Q2 FY26 saw 2.5% sales growth, margin pressure, and reduced full-year guidance.SCSC
Q2 2026 - Sales fell but margins and cash flow improved; acquisitions and hybrid strategy support growth.SCSC
Q4 2024